Corrigendum to "Evaluation of rivaroxaban amorphous solid dispersions physical stability via molecular mobility studies and molecular simulations" [European Journal of Pharmaceutical Sciences 157 (2021) 105642].

IF 4.3 3区医学 Q1 PHARMACOLOGY & PHARMACY

European Journal of Pharmaceutical Sciences Pub Date : 2024-10-15 DOI:10.1016/j.ejps.2024.106932

Afroditi Kapourani, Kalliopi Eleftheriadou, Konstantinos N Kontogiannopoulos, Panagiotis Barmpalexis

引用次数: 0

查看原文本刊更多论文

通过分子迁移率研究和分子模拟评估利伐沙班无定形固体分散体的物理稳定性》[《欧洲药学杂志》157 (2021) 105642]更正。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Pharmaceutical Sciences 医学-药学

CiteScore

9.60

自引率

2.20%

发文量

248

审稿时长

50 days

期刊介绍： The journal publishes research articles, review articles and scientific commentaries on all aspects of the pharmaceutical sciences with emphasis on conceptual novelty and scientific quality. The Editors welcome articles in this multidisciplinary field, with a focus on topics relevant for drug discovery and development. More specifically, the Journal publishes reports on medicinal chemistry, pharmacology, drug absorption and metabolism, pharmacokinetics and pharmacodynamics, pharmaceutical and biomedical analysis, drug delivery (including gene delivery), drug targeting, pharmaceutical technology, pharmaceutical biotechnology and clinical drug evaluation. The journal will typically not give priority to manuscripts focusing primarily on organic synthesis, natural products, adaptation of analytical approaches, or discussions pertaining to drug policy making. Scientific commentaries and review articles are generally by invitation only or by consent of the Editors. Proceedings of scientific meetings may be published as special issues or supplements to the Journal.